JP2023517671A5 - - Google Patents
Info
- Publication number
- JP2023517671A5 JP2023517671A5 JP2022554769A JP2022554769A JP2023517671A5 JP 2023517671 A5 JP2023517671 A5 JP 2023517671A5 JP 2022554769 A JP2022554769 A JP 2022554769A JP 2022554769 A JP2022554769 A JP 2022554769A JP 2023517671 A5 JP2023517671 A5 JP 2023517671A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- thio
- pharmaceutical composition
- inhibitor
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989041P | 2020-03-13 | 2020-03-13 | |
| US62/989,041 | 2020-03-13 | ||
| PCT/US2021/022090 WO2021183873A1 (en) | 2020-03-13 | 2021-03-12 | Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517671A JP2023517671A (ja) | 2023-04-26 |
| JP2023517671A5 true JP2023517671A5 (enExample) | 2024-03-05 |
| JP7829491B2 JP7829491B2 (ja) | 2026-03-13 |
Family
ID=77671975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554769A Active JP7829491B2 (ja) | 2020-03-13 | 2021-03-12 | ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12097213B2 (enExample) |
| EP (1) | EP4117667B1 (enExample) |
| JP (1) | JP7829491B2 (enExample) |
| KR (1) | KR20220154134A (enExample) |
| CN (1) | CN115397428A (enExample) |
| BR (1) | BR112022018238A2 (enExample) |
| CA (1) | CA3170930A1 (enExample) |
| DK (1) | DK4117667T3 (enExample) |
| ES (1) | ES3014683T3 (enExample) |
| FI (1) | FI4117667T3 (enExample) |
| HU (1) | HUE070513T2 (enExample) |
| IL (1) | IL296403A (enExample) |
| MX (1) | MX2022011331A (enExample) |
| PL (1) | PL4117667T3 (enExample) |
| PT (1) | PT4117667T (enExample) |
| WO (1) | WO2021183873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210023107A1 (en) | 2018-03-22 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
| WO2025090539A1 (en) * | 2023-10-22 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2630255B1 (en) * | 2010-10-22 | 2014-09-10 | Roche Diagnostics GmbH | A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide |
| NZ713498A (en) | 2013-04-08 | 2017-07-28 | Univ Texas | Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere |
| CA2991628C (en) * | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| US20180036331A1 (en) | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| WO2017205756A1 (en) | 2016-05-27 | 2017-11-30 | The Board Of Regents Of The University Of Texas System | 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells |
| WO2018049474A1 (en) | 2016-09-16 | 2018-03-22 | Bionomics Limited | Antibody and checkpoint inhibitor combination therapy |
| MA47604A (fr) | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
| US11571459B2 (en) | 2017-04-03 | 2023-02-07 | Oncxerna Therapeutics, Inc. | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents |
| EP3746119A4 (en) * | 2018-02-01 | 2021-11-10 | Merck Sharp & Dohme Corp. | METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY |
| US20210113602A1 (en) | 2018-02-28 | 2021-04-22 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA |
| US20210023107A1 (en) | 2018-03-22 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
-
2021
- 2021-03-12 ES ES21767125T patent/ES3014683T3/es active Active
- 2021-03-12 CN CN202180028952.2A patent/CN115397428A/zh active Pending
- 2021-03-12 PT PT217671254T patent/PT4117667T/pt unknown
- 2021-03-12 MX MX2022011331A patent/MX2022011331A/es unknown
- 2021-03-12 KR KR1020227033906A patent/KR20220154134A/ko active Pending
- 2021-03-12 CA CA3170930A patent/CA3170930A1/en active Pending
- 2021-03-12 HU HUE21767125A patent/HUE070513T2/hu unknown
- 2021-03-12 DK DK21767125.4T patent/DK4117667T3/da active
- 2021-03-12 BR BR112022018238A patent/BR112022018238A2/pt unknown
- 2021-03-12 WO PCT/US2021/022090 patent/WO2021183873A1/en not_active Ceased
- 2021-03-12 IL IL296403A patent/IL296403A/en unknown
- 2021-03-12 JP JP2022554769A patent/JP7829491B2/ja active Active
- 2021-03-12 EP EP21767125.4A patent/EP4117667B1/en active Active
- 2021-03-12 US US17/200,539 patent/US12097213B2/en active Active
- 2021-03-12 PL PL21767125.4T patent/PL4117667T3/pl unknown
- 2021-03-12 FI FIEP21767125.4T patent/FI4117667T3/fi active
-
2024
- 2024-09-09 US US18/829,162 patent/US20240424013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063120A5 (enExample) | ||
| JP2024526145A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP2019519499A5 (enExample) | ||
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2007523862A5 (enExample) | ||
| JP2008528486A5 (enExample) | ||
| JP2022533578A5 (enExample) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| CY1109607T1 (el) | Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων | |
| JP2020523354A5 (enExample) | ||
| JP2009506054A5 (enExample) | ||
| JP2023517671A5 (enExample) | ||
| JP2022510962A5 (enExample) | ||
| Li et al. | Exploring hypoxic biology to improve radiotherapy outcomes | |
| JP2022500479A5 (enExample) | ||
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| JP2019536783A5 (enExample) | ||
| JP2022502399A5 (enExample) | ||
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| JP2023505687A5 (enExample) | ||
| FI4117667T3 (fi) | Syöpien jaksottainen hoito käyttäen 6-tio-dg- ja tarkistuspisteen inhibiittoreita |